share_log

Novavax | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(9.63%)

Novavax | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(9.63%)

诺瓦瓦克斯医药 | SC 13G/A:超过5%持股股东披露文件(修正)-The Vanguard Group(9.63%)
美股SEC公告 ·  2024/11/12 14:50

Moomoo AI 已提取核心信息

The Vanguard Group has filed an amended Schedule 13G with the Securities and Exchange Commission on November 12, 2024, indicating a 9.63% ownership stake in Novavax Inc. This filing, which reflects the state of ownership as of September 30, 2024, reports that The Vanguard Group has beneficial ownership of 15,430,034 shares of Novavax's common stock. The group has shared voting power over 224,741 shares and sole dispositive power over 15,072,218 shares, with an additional shared dispositive power over 357,816 shares. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Novavax and were not held in connection with any transaction having that purpose or effect.
The Vanguard Group has filed an amended Schedule 13G with the Securities and Exchange Commission on November 12, 2024, indicating a 9.63% ownership stake in Novavax Inc. This filing, which reflects the state of ownership as of September 30, 2024, reports that The Vanguard Group has beneficial ownership of 15,430,034 shares of Novavax's common stock. The group has shared voting power over 224,741 shares and sole dispositive power over 15,072,218 shares, with an additional shared dispositive power over 357,816 shares. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Novavax and were not held in connection with any transaction having that purpose or effect.
先锋集团已于2024年11月12日向证券交易委员会提交了修订后的13G表,表明在诺瓦瓦克斯医药公司持有9.63%的股权。这份申报,反映了截至2024年9月30日的所有权状况,报告称先锋集团对诺瓦瓦克斯医药公司的普通股拥有15,430,034股。该集团对224,741股股份享有投票权,单独拥有15,072,218股的行使权,并额外共享对357,816股的行使权。申报声称这些股份并非是为了改变或影响诺瓦瓦克斯医药公司的控制,并且不是在与具有该目的或效果的任何交易有关时持有的。
先锋集团已于2024年11月12日向证券交易委员会提交了修订后的13G表,表明在诺瓦瓦克斯医药公司持有9.63%的股权。这份申报,反映了截至2024年9月30日的所有权状况,报告称先锋集团对诺瓦瓦克斯医药公司的普通股拥有15,430,034股。该集团对224,741股股份享有投票权,单独拥有15,072,218股的行使权,并额外共享对357,816股的行使权。申报声称这些股份并非是为了改变或影响诺瓦瓦克斯医药公司的控制,并且不是在与具有该目的或效果的任何交易有关时持有的。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息